Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years

Continued Collaboration Supports Clinical Trials to Advance Cancer Research across Thousands of Oncology Studies

Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of its 15-year relationship with the National Cancer Institute (NCI), part of the National Institutes of Health. This renewed commitment, spanning an additional five years, consolidates their joint efforts and underscores their dedication to advancing cancer research.

Since the inception of their partnership in 2008, Medidata and the NCI have collaborated across thousands of clinical trials with the joint mission of pioneering the development of promising treatments of cancer - a leading cause of mortality in the United States.

“Medidata’s long-standing partnership with the NCI represents our unwavering commitment to supporting critical oncology research,” says Joseph Schmidt, executive vice president, Customer Success, Services, and Support, Medidata. “It is gratifying that 90% of all oncology approvals last year in the U.S. were developed using Medidata software, and we hope to make an even bigger impact alongside the NCI over the next few years in the fight against cancer.”

The Medidata Platform plays a vital role in supporting complex clinical trials in the healthcare and life sciences sector. By standardizing processes and enhancing data collection, the platform supports accelerated study timelines with the goal of bringing innovative and transformative therapies to patients sooner. Medidata’s solutions have been proven to help advance studies up to five months faster¹.

The company’s unique combination of expertise and best-in-class clinical trial technologies extends its support to public sector research organizations, encompassing over 3,000 academic clinical trials, 223,000 sites, and benefiting 948,000 patients.

Medidata's ongoing commitment to advancing research alongside the NCI underscores the value of partnerships in accelerating the pursuit of groundbreaking therapies that benefit patients.

¹Analysis of difference in median FPI to LPLV time for EDC + at least one additional product vs. EDC only studies (p<0.05)

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com

^© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231004034347/en/